全新分析支持PD-1抑制剂dostarlimab在子宫内膜癌中的应用

2020-04-26 Allan MedSci原创

葛兰素史克公司(GlaxoSmithKline)近日对I / II期GARNET研究作出了最新分析,证明其实验性PD-1单克隆抗体dostarlimab在复发或晚期dMMR子宫内膜癌治疗中的潜在疗效。

葛兰素史克公司(GlaxoSmithKline)近日对I / II期GARNET研究作出了最新分析,证明其实验性PD-1单克隆抗体dostarlimab在复发或晚期dMMR子宫内膜癌治疗中的潜在疗效。葛兰素史克公司(GlaxoSmithKline)去年通过收购Tesaro获得了dostarlimab。该公司肿瘤学研发负责人Axel Hoos说:“我们相信dostarlimab对于晚期或复发dMMR子宫内膜癌患者的临床潜力,这些患者迫切需要其他治疗选择”。

GARNET研究的第一阶段正在评估dostarlimab单药治疗晚期实体瘤患者的疗效。同时,五个扩展队列构成了研究的第二阶段,包括dMMR/微卫星不稳定性高(MSI-H)子宫内膜癌、dMMR子宫内膜癌、dMMR / 非MSI-H子宫内膜癌、非小细胞肺癌和无BRCA突变的铂耐药性卵巢癌。

根据最新分析,该研究包括71例dMMR子宫内膜癌患者。患者每三周一次接受500毫克dostarlimab,然后每六周一次接受1000毫克的剂量,直到疾病进展。该研究的主要终点为客观缓解率(ORR)和缓解持续时间(DoR)。

原始出处:

https://www.firstwordpharma.com/node/1718290

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1912341, encodeId=b376191234129, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jan 29 13:53:16 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708576, encodeId=54361e0857663, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Thu Apr 01 14:53:16 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852350, encodeId=9b1718523506f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Feb 22 10:53:16 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972907, encodeId=646719e29073a, content=<a href='/topic/show?id=2bcc61959a' target=_blank style='color:#2F92EE;'>#dostarlimab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6195, encryptionId=2bcc61959a, topicName=dostarlimab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Sep 02 13:53:16 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278943, encodeId=e68512e8943a9, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Tue Apr 28 01:53:16 CST 2020, time=2020-04-28, status=1, ipAttribution=)]
    2021-01-29 snf701207
  2. [GetPortalCommentsPageByObjectIdResponse(id=1912341, encodeId=b376191234129, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jan 29 13:53:16 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708576, encodeId=54361e0857663, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Thu Apr 01 14:53:16 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852350, encodeId=9b1718523506f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Feb 22 10:53:16 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972907, encodeId=646719e29073a, content=<a href='/topic/show?id=2bcc61959a' target=_blank style='color:#2F92EE;'>#dostarlimab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6195, encryptionId=2bcc61959a, topicName=dostarlimab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Sep 02 13:53:16 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278943, encodeId=e68512e8943a9, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Tue Apr 28 01:53:16 CST 2020, time=2020-04-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1912341, encodeId=b376191234129, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jan 29 13:53:16 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708576, encodeId=54361e0857663, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Thu Apr 01 14:53:16 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852350, encodeId=9b1718523506f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Feb 22 10:53:16 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972907, encodeId=646719e29073a, content=<a href='/topic/show?id=2bcc61959a' target=_blank style='color:#2F92EE;'>#dostarlimab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6195, encryptionId=2bcc61959a, topicName=dostarlimab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Sep 02 13:53:16 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278943, encodeId=e68512e8943a9, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Tue Apr 28 01:53:16 CST 2020, time=2020-04-28, status=1, ipAttribution=)]
    2021-02-22 jklm09
  4. [GetPortalCommentsPageByObjectIdResponse(id=1912341, encodeId=b376191234129, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jan 29 13:53:16 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708576, encodeId=54361e0857663, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Thu Apr 01 14:53:16 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852350, encodeId=9b1718523506f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Feb 22 10:53:16 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972907, encodeId=646719e29073a, content=<a href='/topic/show?id=2bcc61959a' target=_blank style='color:#2F92EE;'>#dostarlimab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6195, encryptionId=2bcc61959a, topicName=dostarlimab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Sep 02 13:53:16 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278943, encodeId=e68512e8943a9, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Tue Apr 28 01:53:16 CST 2020, time=2020-04-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1912341, encodeId=b376191234129, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jan 29 13:53:16 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708576, encodeId=54361e0857663, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Thu Apr 01 14:53:16 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852350, encodeId=9b1718523506f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Feb 22 10:53:16 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972907, encodeId=646719e29073a, content=<a href='/topic/show?id=2bcc61959a' target=_blank style='color:#2F92EE;'>#dostarlimab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6195, encryptionId=2bcc61959a, topicName=dostarlimab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Sep 02 13:53:16 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278943, encodeId=e68512e8943a9, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Tue Apr 28 01:53:16 CST 2020, time=2020-04-28, status=1, ipAttribution=)]

相关资讯

根据与澳大利亚加拿大的新同步审查计划,美国FDA批准Keytruda与乐伐替尼组合治疗子宫内膜癌

在Orbis项目下,FDA与加拿大卫生部和澳大利亚治疗用品管理局(TGA)合作审查了Eisai的Lenvima(lenvatinib)与Merck的Keytruda(pembrolizumab)联合治疗子宫内膜癌的申请。乐伐替尼(Lenvima)是肝癌患者耳熟能详的靶向药。是一个多靶点的抑制剂,靶点包括VEGFR-1、VEGFR-2、VEGFR-3、FGFR1、PDGFR、cKit、Ret。

2019 ESMO:癌症新闻大爆炸

在欧美裁员之后,赛诺菲在日本的规模正在缩小。大型制药公司的大多数首席执行官都有自己的中文名字,以新方式表明他们对世界第二大药品市场的关心。在今年的欧洲医学肿瘤学会(ESMO)年会上,Astellas和Seattle Genetics公布了抗体-药物结合物的积极成果,默克公司和Eisai详细介绍了Keytruda-Lenvima组合获胜和Chi-Med宣传VEGFR抑制剂surufatinib的神经

Cancer:子宫内膜增生高子宫内膜癌风险的突变特征

背景:子宫内膜增生是子宫内膜样腺癌(EMC)的先兆,子宫内膜样腺癌是最常见的子宫癌。子宫内膜增生进展成癌的可能性可以通过子宫内膜增生的组织学分类来评估,尽管这些分类是主观的,在病理学家中只能在一定程度

Am J Surg Pathol:年轻女性子宫内膜浆液性癌的独特的分子、形态、临床等特征

根据Bokhman的描述,子宫内膜癌(EC)既往被分为I型(低度恶性、激素依赖性、年轻患者、预后良好)或II型(高度恶性、激素非依赖性、老年患者、预后不良)。

《国际妇产科联盟(FIGO)2018癌症报告:子宫内膜癌诊治指南》解读

子宫内膜癌虽然总体预后较好, 但高级别的子宫内膜癌有复发的倾向, 由于复发性子宫内膜癌预后较差,因此临床上需重视对复发的管理。针对肿瘤生物学制订的治疗方案是平衡治疗功效与不良反应的最佳策略,其基本治疗包括子宫切除术和双侧附件切除术。淋巴结切除术能够识别需要辅助放疗和化疗的淋巴结受累患者( 前哨淋巴结活检的研究正在进行中) 。辅助放疗用于有高危因素的Ⅰ-Ⅲ期患者和淋巴结阴性的I 期患者。在晚期患者中

NATURE:子宫内膜癌相关突变可能开始于童年

所有的正常体细胞都被认为是可以获得突变的,但是我们对于正常体细胞中的突变速率、模式、原因和后果的理解是有限的。

拓展阅读

2024 ESGO|妇科肿瘤领域重磅研究速览!

ESGO作为最具影响力的妇科肿瘤学学术会议之一,为妇科肿瘤领域专家学者搭建了高质量的学习和交流平台,致力于及时传递妇科肿瘤领域最前沿的学术研究进展。「医悦汇」整理妇科肿瘤重磅研究摘要,以供读者参考!

Gynecol. Oncol | 肥胖与子宫内膜癌免疫治疗反应的关系:肥胖患者对帕博利珠单抗治疗反应更佳

该研究旨在通过回顾性单中心分析,评估肥胖与子宫内膜癌患者接受帕博利珠单抗治疗效果的关系,肥胖与子宫内膜癌患者接受帕博利珠单抗治疗时的更高的疾病控制率和无进展生存期相关。

病理干货 | 子宫内膜癌分子分型介绍

子宫内膜癌是发生于子宫内膜的一组上皮性恶性肿瘤,在 2020 年全球新发病例为417367 例,死亡病例为 97370 例。

妇科肿瘤FIGO分期与TNM分期对比分享

妇科肿瘤FIGO分期与TNM分期对比,临床医生别错过,收藏起来慢慢看。

放置曼月乐后发生子宫内膜癌1例及文献回顾!值得学习!

子宫内膜癌发生在放置曼月乐的女性中很罕见。本文通过介绍一例因经量多放置曼月乐,4年后发生子宫内膜癌的病例,并复习有关文献,希望引起大家重视,提高对放置曼月乐后定期随访重要性的认识。

JCO | 度伐利尤单抗加卡铂/紫杉醇,随后维持度伐利尤单抗联合或不联合奥拉帕利作为晚期子宫内膜癌患者的一线治疗:Ⅲ期DUO-E试验

旨在研究度伐利尤单抗加化疗后维持度伐利尤单抗加或不加奥拉帕利作为子宫内膜癌一线治疗的疗效,将度伐利尤单抗添加到铂类化疗后维持度伐利尤单抗加或不加奥拉帕利,与单独化疗相比,显著改善了患者的无进展生存期。